Auxilium Pharmaceuticals — Q2 2014 Earnings Presentation
31 slides from Auxilium Pharmaceuticals's earnings presentation, Aug 7, 2014
Slide 1: 2Q 2014 Financial Results Corporate Overview
Auxilium Pharmaceuticals, Inc | 2014 2Q 2014 Financial Results Corporate Overview August 7, 2014 .
Slide 2: Forward-looking statements
We will make various remarks during this presentation that constitute "forward-looking statements" for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements regarding: the Company's expected financial performance, including the degree
Slide 3: No Offer or Solicitation
3 Auxilium Pharmaceuticals, Inc. | 2014 No Offer of Solicitation No Offer or Solicitation This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdict
Slide 4: Agenda
4 Auxilium Pharmaceuticals, Inc. | 2014 Agenda Corporate Progress – Merger with QLT: a Platform for Growth 2Q 2014 Commercial & Financial Performance – Financial Results – Highlights by Product Franchise Strategic Priorities & Upcoming Milestones Question & Answer Session
Slide 5: Auxilium Executing Multi-Phase Growth Strategy
5 Auxilium Pharmaceuticals, Inc. | 2014 Auxilium Executing Multi-Phase Growth Strategy Expanded product portfolio and established leadership position in men’s healthcare Acquisition of Actient, STENDRA in-licensing Grew from 2 to 12 products PHASE ONE: 2013 PHASE THREE: 2015 & Beyond Diversify produ
Slide 6: 2Q 2014: Financial Results
6 Auxilium Pharmaceuticals, Inc. | 2014 2Q 2014: Financial Results1 Amounts in $MM Except Per Share Amounts 2Q 2013 2Q 2014 Total Revenues $100.5 $83.0 Cost of Goods Sold (non-GAAP) 22.7 30.0 Gross Profit $77.8 $53.0 % of Revenues 77% 64% Operating Expenses (non-GAAP): Research & Development $12.9 $
Slide 7: 2014 Financial Guidance
7 Auxilium Pharmaceuticals, Inc. | 2014 2014 Financial Guidance $ Millions1 Global Net Revenues: $380-420 R&D Expenses (Non-GAAP): $40-45 SG&A Expenses (Non-GAAP): $245-250 Net Interest Expense (Non-GAAP): $20-22 Net Income (Loss) (Non-GAAP): $0-(15) Gross Margin: 76-77% 1 See Appendix for reconcili
Slide 8: 2014: Future Product Growth Potential
8 Auxilium Pharmaceuticals, Inc. | 2014 2014: Future Product Growth Potential $315* $189.5* +66% All numbers $ millions * 2013 number represents total revenues ($400.7M) less $211.2M for Testim; 2014 number represents midpoint of 2014 guidance ($400M) less $85M for Testim; We believe that reporting
Slide 9: Diversified Product Portfolio and R&D Pipeline
9 Auxilium Pharmaceuticals, Inc. | 2014 Diversified Product Portfolio and R&D Pipeline Erectile Dysfunction Low Testosterone Peyronie’s Disease Adhesive Capsulitis Cellulite Orthopedics/ Dermatology PIPELINE TREATMENTS MEN’S HEALTHCARE Additional medications include: Ophthalmology* Impaired Dark Ada
Slide 10: Testim Franchise: Managing a Mature Product
10 Auxilium Pharmaceuticals, Inc. | 2014 Testim Franchise: Managing a Mature Product Strategic rationale for June 2014 launch of a Testim Authorized Generic (AG) – Launched with partner Prasco in mid-June – Proactive strategy to manage the Testim life cycle and increase and expand product franchise
Slide 11: Testim Franchise: AG Driving Increased Access
11 Auxilium Pharmaceuticals, Inc. | 2014 Testim Franchise: AG Driving Increased Access Testim Franchise: NRx Share of TRT Gel Market IMS Health, 2014; based on all data available as of August 4, 2014 Testim AG launched June 11, 2014 Testim: $11.9 Million Testim Authorized Generic: $13.3 Million $25.
Slide 12: TESTOPEL: Buy-In Impact Expected
12 Auxilium Pharmaceuticals, Inc. | 2014 Only FDA-approved long-acting testosterone pellet available – Lasts ~3-4 months 15% price increase on April 1 believed to have driven $12-14 million product buy-in in 1Q 2014 – A 2Q impact was expected – Additional wholesaler destocking believed to have affec
Slide 13: STENDRA: First ED Drug Approved in Years
13 Auxilium Pharmaceuticals, Inc. | 2014 STENDRA: First ED Drug Approved in 10 Years Exciting and distinct product profile – Rapid – can be taken 30 minutes before sexual activity – Able to be taken with food and modest alcohol – Designed to be a selective PDE5 inhibitor; low incidence of AEs in cli
Slide 14: STENDRA: Initial Launch Traction Continues
14 Auxilium Pharmaceuticals, Inc. | 2014 STENDRA: Initial Launch Traction Continues STENDRA Rx Since Launch IMS Health, 2014; based on all data available as of June 30, 2014; * Revenues recognized by Company at time product shipped to wholesalers $6.1 Million in 2Q Revenues* Increasing number of tot
Slide 15: Weekly STENDRA TRx Share of Oral ED Market
15 Auxilium Pharmaceuticals, Inc. | 2014 Weekly STENDRA TRx Share of Oral ED Market STENDRA: Initial Launch Traction Continues IMS Health, 2014; based on all data available as of August 4, 2014 3.2% 1.4% 0.4% Jan Feb Mar Apr May Jun Jul
Slide 16: STENDRA: Quarterly Rx Breakdown
16 Auxilium Pharmaceuticals, Inc. | 2014 STENDRA: Initial Launch Traction Continues IMS Health, 2014; based on all data available as of July 22, 2014; products are registered trademarks of their respective owners * Rx not categorized by IMS Quarterly STENDRA Rx Breakdown 25% 29% 15% 6% 26% Launch-to
Slide 17: edex: Continued Market Leadership
17 Auxilium Pharmaceuticals, Inc. | 2014 edex: Continued Market Leadership Market-leading injectable ED treatment – Rapid onset; convenient single-dose dual-chamber cartridge – Non-oral ED treatments represent ~0.5% of total ED TRx1 2Q 2014 revenues of $7.5 million – 50% increase over 2Q 2013 51.8%
Slide 18: XIAFLEX: Overall Product Performance
18 Auxilium Pharmaceuticals, Inc. | 2014 XIAFLEX: Overall Product Performance Continued launch traction in Peyronie’s disease – Strong momentum since launch in January 2014 Stable growth traction in Dupuytren’s contracture 2Q 2014: $26.3M XIAFLEX U.S. Revenues by Quarter +75%
Slide 19: XIAFLEX in DC: Stable Growth Traction
19 Auxilium Pharmaceuticals, Inc. | 2014 XIAFLEX in DC: Stable Growth Traction 7% increase in vial sales over 2Q 2013 Stable XIAFLEX market share – 29% YTD through May Increasing awareness & demand for DC procedures – Rolling 12-month total procedures: April 2014: 66,324 April 2013: 63,201 4.9 % inc
Slide 20: XIAFLEX: First and Only Approved PD Treatment
20 Auxilium Pharmaceuticals, Inc. | 2014 XIAFLEX: First and Only Approved PD Treatment First and only FDA-approved treatment proven effective for PD in men with a palpable plaque and a curvature deformity of >30 degrees at the start of therapy
Slide 21: XIAFLEX for PD: Focused Launch Strategy
21 Auxilium Pharmaceuticals, Inc. | 2014 XIAFLEX for PD: Focused Launch Strategy Category Invasive Surgical1 Invasive Non- Surgical1 Non-Invasive No Treatment2 Description / Examples Plication, grafting, prosthesis Verapamil injection Vitamin E, potaba, colchicine Patient Counts 1,500 – 2,000 3,500
Slide 22: XIAFLEX for PD: Strong Launch Momentum
22 Auxilium Pharmaceuticals, Inc. | 2014 XIAFLEX for PD: Strong Launch Momentum Certification of Top Target Urologists Phase I & II (n=432) 12% 88% 645 Total Sites Certified 1,108 Total Physicians Certified Auxilium; All numbers as of June 30, 2014
Slide 23: XIAFLEX for PD: Payer Reimbursement
23 Auxilium Pharmaceuticals, Inc. | 2014 XIAFLEX for PD: Payer Reimbursement Auxilium Advantage; All numbers as of June 30, 2014 93% Approved 53% Decision Made 47% Currently in Process PD Patients Submitted Through June 30, 2014 3,535 1,709 143 1,683
Slide 24: XIAFLEX for PD: Strong Launch Momentum
24 Auxilium Pharmaceuticals, Inc. | 2014 XIAFLEX for PD: Strong Launch Momentum 3,350 Vials Total * Vials s hipped to physicians repres ents in-market demand. Rev enues for PD are rec ognized by Company when sold to whol esalers. Estimates do not include vials shipped to large hospital centers that
Slide 25: Strategic Priorities & Milestones Moving Forward
25 Auxilium Pharmaceuticals, Inc. | 2014 Strategic Priorities & Milestones Moving Forward – Successfully launch two new products: STENDRA for ED and XIAFLEX for PD – Grow TESTOPEL and edex use with urologists – Drive XIAFLEX to standard of care in Dupuytren’s – Closely manage and strategically resou
Slide 26: Appendix
26 Auxilium Pharmaceuticals, Inc. | 2014 Appendix
Slide 27: 2Q 2014 Net Revenue Details
27 Auxilium Pharmaceuticals, Inc. | 2014 2Q 2014 Net Revenue Details Inc rease Increase 2014 2013 (Decrease) 2014 2013 (Dec rease ) Testim revenues- Net U.S. revenues - brand $11.9 $53.2 -78% $22.8 $98.5 -77% Net U.S. revenues - AG 13.3 - N/A 13.3 - N/A International revenues 0.9 1.2 -25% 1.8 1.4 29
Slide 28: 2Q Reconciliation: GAAP to Non-GAAP Net Loss
28 Auxilium Pharmaceuticals, Inc. | 2014 2Q Reconciliation: GAAP to Non-GAAP Net Loss 3 Months Ended June 30, 2014 3 Months Ended June 30, 2013 GAAP Adjustments Non-GAAP GAAP Adjustments Non-GAAP Net revenues* 83.0 $ - $ 83.0 $ 100.5 $ - $ 100.5 $ Operating expenses: Cost of goods sold 30.1 (0.1) (a
Slide 29: 2Q Reconciliation: GAAP to Non-GAAP Net Loss adjustments
29 Auxilium Pharmaceuticals, Inc. | 2014 2Q Reconciliation: GAAP to Non-GAAP Net Loss 3 Months 3 Months Ended June 30, 2 014 Ended June 30 , 201 3 Adjustments to: (a ) Costs of goods sold: Employee stock-based compensation (1) (0.1) - Acquired inventory step-up value (2) - (4.5) (0.1) $ (4.5) $ (b)
Slide 30: YTD Reconciliation: GAAP to Non-GAAP Net Loss
30 Auxilium Pharmaceuticals, Inc. | 2014 YTD Reconciliation: GAAP to Non-GAAP Net Loss 6 Months Ended June 30, 2014 6 Months Ended June 30, 2013 GAAP Adjustments Non-GAAP GAAP Adjustments Non-GAAP Net revenues* 171.5 $ - $ 171.5 $ 166.7 $ - $ 166.7 $ Operating expenses: Cost of goods sold 48.2 (0.1)
Slide 31: YTD Reconciliation: GAAP to Non-GAAP Net Loss adjustments
31 Auxilium Pharmaceuticals, Inc. | 2014 YTD Reconciliation: GAAP to Non-GAAP Net Loss 6 Months 6 Months Ended June 30, 2 014 Ended June 3 0, 20 13 Adjustments to: (a ) Costs of goods sold: Employee stock-based compensation (1) (0.1) (0.1) Acquired inventory step-up value (2) - (4.5) (0.1) $ (4.6) $
Auxilium Pharmaceuticals — Q2 2014 Earnings Presentation on 6ix